Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Pietro Di Ciaccio^{1

2}, Georgia McCaughan^{1

2

3}, Judith Trotman^{3

4}, Phoebe Joy Ho^{3

5}, Chan Y Cheah^{6

7

8}, Shane Gangatharan^{8

9}, Joel Wight^{10

11}, Matthew Ku^{11

12}, Hang Quach^{11

12}, Robin Gasiorowski^{3

4}, Mark N Polizzotto^{1

2

13}, Henry Miles Prince^{11

14

15}, Stephen Mulligan^{3

16}, Constantine S Tam^{11

12

14}, Gareth Gregory¹⁷, Greg Hapgood¹⁸, Andrew Spencer^{11

19}, Michael Dickinson^{11

14}, Maya Latimer²⁰, Anna Johnston^{21

22}, Tasman Armytage²³, Cindy Lee²⁴, Tara Cochrane^{25

26}, Leanne Berkhahn^{27

28}, Robert Weinkove^{29

30}, Richard Doocey²⁷, Simon J Harrison^{11

14}, Nicholas Webber³¹, Hui-Peng Lee³², Scott Chapman³³, Belinda A Campbell^{11

34}, Simon D J Gibbs^{35

36}, Nada Hamad^{1

2

3}

Affiliations

¹ Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
² University of New South Wales, Sydney, New South Wales, Australia.
³ University of Sydney, Sydney, New South Wales, Australia.
⁴ Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
⁵ Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁶ Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
⁷ Department of Haematology, Pathwest Laboratory Medicine, Perth, Western Australia, Australia.
⁸ University of Western Australia, Perth, Western Australia, Australia.
⁹ Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
¹⁰ Townsville University Hospital, Townsville, Queensland, Australia.
¹¹ University of Melbourne, Melbourne, Victoria, Australia.
¹² Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
¹³ The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹⁴ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
¹⁵ Department of Haematology, Epworth Healthcare, Melbourne, Victoria, Australia.
¹⁶ Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹⁷ Department of Haematology, Monash Health, Melbourne, Victoria, Australia.
¹⁸ Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
¹⁹ Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.
²⁰ Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
²¹ Department of Haematology, The Royal Hobart Hospital, Hobart, Tasmania, Australia.
²² University of Tasmania, Hobart, Tasmania, Australia.
²³ Department of Haematology, Gosford Hospital, Gosford, New South Wales, Australia.
²⁴ Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
²⁵ Department of Haematology, Gold Coast University Hospital, Southport, Queensland, Australia.
²⁶ Griffith University, Brisbane, Queensland, Australia.
²⁷ Department of Haematology, The Auckland City Hospital, Auckland, New Zealand.
²⁸ University of Auckland, Auckland, New Zealand.
²⁹ Department of Haematology, Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
³⁰ Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
³¹ Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
³² Department of Haematology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, South Australia, Australia.
³³ Department of Infectious Diseases, St Vincent's Hospital, Sydney, New South Wales, Australia.
³⁴ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³⁵ Department of Haematology, Eastern Health, Melbourne, Victoria, Australia.
³⁶ Monash University, Melbourne, Victoria, Australia.

PMID: 32415723
DOI: 10.1111/imj.14859

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Pietro Di Ciaccio et al. Intern Med J. 2020 Jun.

. 2020 Jun;50(6):667-679.

doi: 10.1111/imj.14859. Epub 2020 May 15.

Authors

Affiliations

¹ Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
² University of New South Wales, Sydney, New South Wales, Australia.
³ University of Sydney, Sydney, New South Wales, Australia.
⁴ Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
⁵ Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁶ Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
⁷ Department of Haematology, Pathwest Laboratory Medicine, Perth, Western Australia, Australia.
⁸ University of Western Australia, Perth, Western Australia, Australia.
⁹ Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
¹⁰ Townsville University Hospital, Townsville, Queensland, Australia.
¹¹ University of Melbourne, Melbourne, Victoria, Australia.
¹² Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
¹³ The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹⁴ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
¹⁵ Department of Haematology, Epworth Healthcare, Melbourne, Victoria, Australia.
¹⁶ Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹⁷ Department of Haematology, Monash Health, Melbourne, Victoria, Australia.
¹⁸ Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
¹⁹ Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.
²⁰ Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
²¹ Department of Haematology, The Royal Hobart Hospital, Hobart, Tasmania, Australia.
²² University of Tasmania, Hobart, Tasmania, Australia.
²³ Department of Haematology, Gosford Hospital, Gosford, New South Wales, Australia.
²⁴ Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
²⁵ Department of Haematology, Gold Coast University Hospital, Southport, Queensland, Australia.
²⁶ Griffith University, Brisbane, Queensland, Australia.
²⁷ Department of Haematology, The Auckland City Hospital, Auckland, New Zealand.
²⁸ University of Auckland, Auckland, New Zealand.
²⁹ Department of Haematology, Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
³⁰ Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
³¹ Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
³² Department of Haematology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, South Australia, Australia.
³³ Department of Infectious Diseases, St Vincent's Hospital, Sydney, New South Wales, Australia.
³⁴ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³⁵ Department of Haematology, Eastern Health, Melbourne, Victoria, Australia.
³⁶ Monash University, Melbourne, Victoria, Australia.

PMID: 32415723
DOI: 10.1111/imj.14859

Abstract

The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.

Keywords: COVID-19; chronic lymphocytic leukaemia; lymphoma; myeloma.

PubMed Disclaimer

Cited by

COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: biological findings and therapeutic challenges.
Charra B, Ellouadghiri A, Magramane A, Kebbou T, Damaan K, Maghfour A, Seddiki K, Ezzouine H. Charra B, et al. Pan Afr Med J. 2020 Aug 17;36:286. doi: 10.11604/pamj.2020.36.286.24361. eCollection 2020. Pan Afr Med J. 2020. PMID: 33117480 Free PMC article.
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel).
Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, Rodriguez-Abreu D, Martínez F, Barrajón E, Méndez M, Calvo V, Provencio M. Franco F, et al. Curr Oncol. 2021 Mar 16;28(2):1249-1255. doi: 10.3390/curroncol28020118. Curr Oncol. 2021. PMID: 33809772 Free PMC article.
Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.
Tsilingiris D, Nasiri-Ansari N, Spyrou N, Magkos F, Dalamaga M. Tsilingiris D, et al. Cancers (Basel). 2022 May 19;14(10):2494. doi: 10.3390/cancers14102494. Cancers (Basel). 2022. PMID: 35626099 Free PMC article. Review.
Impact of COVID-19 in patients with lymphoid malignancies.
Riches JC. Riches JC. World J Virol. 2021 May 25;10(3):97-110. doi: 10.5501/wjv.v10.i3.97. World J Virol. 2021. PMID: 34079692 Free PMC article. Review.
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19.
Rajabto W, Chandika V, Harahap AS, Ham MF. Rajabto W, et al. Int Med Case Rep J. 2022 Jun 1;15:269-273. doi: 10.2147/IMCRJ.S348718. eCollection 2022. Int Med Case Rep J. 2022. PMID: 35677855 Free PMC article.

See all "Cited by" articles

References

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
1. Fauci AS, Lane HC, Redfield RR. Covid-19-navigating the uncharted. N Engl J Med 2020; 382: 1268-9.
1. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; 323: 1545-6.
1. Kim YJ, Lee ES, Lee YS. High mortality from viral pneumonia in patients with cancer. Infect Dis (Lond) 2019; 51: 502-9.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Affiliations

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Authors

Affiliations

Abstract

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical